在癌癥治療的漫漫探索途中,抗體-藥物偶聯(lián)物(ADCs)正如同一顆閃亮的明星,迅速嶄露頭角,成為現(xiàn)代醫(yī)學(xué)界非常具有潛力的治療手段。這種革新性的療法通過(guò)使用特異性抗體將細(xì)胞毒性藥物精確遞送至癌細(xì)胞,從而顯著減少對(duì)健康細(xì)胞的傷害。最近,科學(xué)家們?cè)诳拱┧幬镩_(kāi)發(fā)方面取得了重大突破,進(jìn)一步推動(dòng)了這一領(lǐng)域的進(jìn)展。
意大利IRCCS圣拉斐爾科學(xué)研究所的研究團(tuán)隊(duì)開(kāi)發(fā)出了一種全新的ADC,這種ADC由Zoledronic Acid和抗-CD30的布倫妥單抗-維多。˙rentuximab-Vedotin)組成。研究結(jié)果表明,這種ADC不僅表現(xiàn)出顯著的抗淋巴瘤活性,還能夠激發(fā)免疫反應(yīng)。
相關(guān)論文“Antibody–Drug Conjugate Made of Zoledronic Acid and the Anti-CD30 Brentuximab–Vedotin Exert Anti-Lymphoma and Immunostimulating Effects”已于2024年5月17日發(fā)表在國(guó)際權(quán)威期刊《Cells》上,標(biāo)志著該領(lǐng)域研究邁出了重要一步。
在此次研究過(guò)程中,科學(xué)家們使用新一代活細(xì)胞實(shí)時(shí)動(dòng)態(tài)成像及功能分析系統(tǒng)CellCyte X對(duì)ADC藥物處理的多種CD30陽(yáng)性的淋巴瘤細(xì)胞系進(jìn)行了長(zhǎng)時(shí)間成像(24小時(shí)、48小時(shí)和72小時(shí)),并結(jié)合CELLCYTE Studio軟件對(duì)采集到的數(shù)據(jù)進(jìn)行了詳細(xì)分析,通過(guò)實(shí)時(shí)檢測(cè)細(xì)胞生長(zhǎng)曲線和存活率,評(píng)估ADC藥物對(duì)CD30陽(yáng)性淋巴瘤細(xì)胞增值的抑制效果以及對(duì)細(xì)胞凋亡的誘導(dǎo)能力。
實(shí)驗(yàn)數(shù)據(jù)(Figure 6. Figure 7.)顯示,這種新型ADC藥物能夠高效進(jìn)入靶細(xì)胞并誘導(dǎo)細(xì)胞凋亡。此外,實(shí)驗(yàn)還發(fā)現(xiàn),這種ADC藥物能夠顯著刺激T細(xì)胞的活性,增強(qiáng)免疫系統(tǒng)的抗腫瘤能力。
Figure 6. Reduction of HL-cell growth in the presence of Bre–Ved–ZA compared to Bre–Ved. (A) Images of KMH2 cell cultures, without or with 2 µg/mL of Bre–Ved–ZA or Bre–Ved, taken at 24, 48, and 72 h with the CELLCYTE XTM imaging recorder are shown. Magnification 50×; one well/each time point is shown. Bar: 100 µm. (B) Cell area calculated by image analysis (CELLCYTE Studio software) on images of proliferating KMH2 cell cultures, without or with Bre–Ved–ZA or Bre–Ved (2.0 µg/mL or 0.2 µg/mL) taken at 24, 48, 72 h, expressed as mm2. (C) Cell area, calculated as in (A), of L428 or L540 clusters at 24, 48, and 72 h expressed in mm2. Results are the mean ± SD of three independent experiments from 4 replicated wells. *** p < 0.001 of Bre–Ved–ZA vs. Bre–Ved at 2.0 µg/mL).
Figure 7 HL-cell death induced by Bre–Ved–ZA ADC compared to Bre–Ved. (A) Images of KMH2 cells stained with C.LIVE Tox green fluorescent probe (20 nM) and cultured without or with 2 µg/mL or 0.2 µg/mL Bre–Ved–ZA or Bre–Ved, analyzed at 24, 48, and 72 h with the CELLCYTE XTM imaging recorder. Magnification 50×; one representative well/time point is shown. Bar: 100 µm. (B) Fluorescence intensity measured with the CELLCYTE Studio software on images of KMH2 cell cultures, without or with Bre–Ved–ZA or Bre–Ved (2 µg/mL or 0.2 µg/mL) taken at 24, 48, and 72 h, and expressed in arbitrary units (a.u.). (C) Fluorescence intensity measured as in A on L428 and L540 cell lines cultured with or without Bre–Ved–ZA or Bre–Ved for the indicated time points (a.u.). Results are the mean ± SD of three independent experiments from 4 replicated wells. *** p > 0.001 of Bre–Ved–ZA vs. Bre–Ved at 2.0 µg/mL.
研究團(tuán)隊(duì)在動(dòng)物模型上進(jìn)行了進(jìn)一步驗(yàn)證。結(jié)果顯示,這種新型ADC藥物不僅顯著抑制了腫瘤的生長(zhǎng),還延長(zhǎng)了實(shí)驗(yàn)動(dòng)物的生存期。更加令人振奮的是,這種藥物展現(xiàn)出良好的安全性,副作用控制在可接受范圍內(nèi)。
此項(xiàng)研究的成功不僅為淋巴瘤的治療帶來(lái)了新的希望,還為ADC藥物的研發(fā)提供了新的思路。CellCyte X在此研究中的應(yīng)用展示了現(xiàn)代科技在醫(yī)學(xué)研究中的巨大潛力,該技術(shù)可以通過(guò)更加精準(zhǔn)和高效的方式,加速科學(xué)發(fā)現(xiàn),助力新藥研發(fā)。
CellCyte X 技術(shù)亮點(diǎn)
提高細(xì)胞活率:能內(nèi)置在任何廠牌的培養(yǎng)箱中,降低實(shí)驗(yàn)過(guò)程中對(duì)細(xì)胞的干擾。
實(shí)時(shí)收集與分析數(shù)據(jù):在整個(gè)實(shí)驗(yàn)過(guò)程中,可實(shí)時(shí)對(duì)數(shù)據(jù)進(jìn)行收集與處理。
通量高:可同時(shí)設(shè)置6塊板位,更大限度地提高了實(shí)驗(yàn)通量。
開(kāi)放式設(shè)計(jì):分別獨(dú)立設(shè)置檢測(cè)程序,可兼容多品牌不同規(guī)格孔板和培養(yǎng)皿。
三通道熒光:增強(qiáng)的輪廓成像模式,除了明場(chǎng),還有紅、藍(lán)、綠3色熒光通道。
數(shù)據(jù)分析功能強(qiáng)大:根據(jù)實(shí)驗(yàn)需求每次可采集并存儲(chǔ)數(shù)千張500萬(wàn)像素的高清圖像。
設(shè)計(jì)緊湊:儀器結(jié)構(gòu)設(shè)計(jì)緊湊,易于安裝與維護(hù),降低維護(hù)成本。
軟件平臺(tái)簡(jiǎn)潔直觀:高效便捷的模塊化軟件設(shè)置和數(shù)據(jù)分析,可輸出圖片、視頻、生長(zhǎng)曲線等多參數(shù)。
總之,新一代活細(xì)胞實(shí)時(shí)動(dòng)態(tài)成像及功能分析系統(tǒng)CellCyte X在本次抗淋巴瘤研究中起到了關(guān)鍵作用,不僅提升了實(shí)驗(yàn)效率和數(shù)據(jù)準(zhǔn)確度,更展示了其在未來(lái)醫(yī)學(xué)研究中的廣闊應(yīng)用前景。我們期望,這一系列研究成果能激勵(lì)更多的科學(xué)家和藥物研發(fā)者,以更加開(kāi)放和創(chuàng)新的態(tài)度繼續(xù)攻克癌癥等重大疾病的治療難關(guān),為人類健康事業(yè)做出更大貢獻(xiàn)。
如果您對(duì)科研新動(dòng)向感興趣,歡迎關(guān)注我們的公眾號(hào)。我們將持續(xù)為您帶來(lái)第一手的科學(xué)研究進(jìn)展和突破,讓我們一起見(jiàn)證科學(xué)的力量,推動(dòng)醫(yī)學(xué)科研的發(fā)展!